There are 2949 resources available
1907P - Application of anti-PD1 drugs before or during thoracic radiotherapy increases the incidence of radiation pneumonia compared to the application after radiotherapy
Presenter: Nan Zhang
Session: E-Poster Display
Resources:
Abstract
1908P - FGFR1-4 mutations are associated with immunotherapy outcomes in patients with non-small cell lung cancer
Presenter: Ji Chen
Session: E-Poster Display
Resources:
Abstract
1909P - Treatment patterns and outcomes in malignant pleural mesothelioma (MPM) in England: A nationwide CAS registry analysis from the I-O optimise initiative
Presenter: Paul Baas
Session: E-Poster Display
Resources:
Abstract
1910P - Outcomes of systemic therapy after first line therapy in patients (p) with malignant pleural mesothelioma (MPM)
Presenter: Susana Cedres
Session: E-Poster Display
Resources:
Abstract
1911P - Characteristics and real-world outcomes of young lung cancer patients, age ≤45 years, treated in a UK specialist centre
Presenter: Daniel Hughes
Session: E-Poster Display
Resources:
Abstract
1912TiP - NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery
Presenter: Rajiv Shah
Session: E-Poster Display
Resources:
Abstract
1915P - The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial
Presenter: Christine Dierks
Session: E-Poster Display
Resources:
Abstract
1916P - Larotrectinib treatment of advanced TRK fusion thyroid cancer
Presenter: Maria E. Cabanillas
Session: E-Poster Display
Resources:
Abstract
1917P - Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial
Presenter: Bryan Haugen
Session: E-Poster Display
Resources:
Abstract
1918P - Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)
Presenter: Marcia S. Brose
Session: E-Poster Display
Resources:
Abstract